Asthma, Allergies and Immune Diseases
| Code | School | Level | Credits | Semesters |
| PHAR2039 | Pharmacy | 2 | 20 | Autumn Malaysia |
- Code
- PHAR2039
- School
- Pharmacy
- Level
- 2
- Credits
- 20
- Semesters
- Autumn Malaysia
Summary
Amongst the more common disorders encountered by both community and hospital pharmacists are those affecting the respiratory system; asthma & chronic obstructive pulmonary disorder. These have significant inflammatory components, which can be illustrated by consideration of two other very common disorders; atopy and eczema. Treatment of inflammatory diseases will be illustrated by consideration of rheumatoid arthritis and inflammatory bowel diseases. This module aims to illustrate molecular and cellular mechanisms underlying these pathological states; how therapeutic intervention is designed to treat these states and how better medicines can be generated for these conditions. Examples of topics within the module include:
a. The regulation of smooth muscle tone and mucus production; the role of inflammatory cells.
b. Current and future pharmacotherapies to treat respiratory and inflammatory conditions; molecular and cellular targets.
c. Delivery systems (inhalers, etc.) for pharmacotherapies and their appropriate usage and supply.
Assessment
- 30% Examsys: Examsys (mid-term)
- 70% OSCE (24-hour)
Learning Outcomes
MLO1: Describe knowledge in molecular and cellular mechanisms associated with respiratory and inflammatory disorders, and the research breakthroughs in biology and pharmaceutical sciences underpinning current and future strategies for treating these disorders. (C2-Understanding)
MLO 2: Apply knowledge associated with respiratory and inflammatory disorders to assess the appropriate management of these disorders in both mechanistic and clinical terms. (C3-Applying)
MLO3: Demonstrate a range of appropriate diagnostic or physiological testing techniques to inform clinical decision making, including the role of pharmacist in optimising and advising about therapies, correct uses of devices and disease self-management. (P5-Complex Overt Responses)
MLO4: Display effective communication with patients about the safe and effective use of devices (e.g. inhalers), their prescribed treatment (e.g. oral, eye, nasal preparations), and available options in a way which promotes understanding. (A5-Characterisation)
MLO5: Recognise ethical dilemmas and respond in accordance with relevant codes of conduct. (C4-Analysing)